These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 20574648)

  • 21. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
    Nishimoto N; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Azuma J; Kishimoto T
    Mod Rheumatol; 2009; 19(1):12-9. PubMed ID: 18979150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.
    Bykerk VP; Östör AJ; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Graninger W; Bensen W; Nurmohamed MT; Krause A; Bernasconi C; Aassi M; Sibilia J
    Clin Rheumatol; 2015 Mar; 34(3):563-71. PubMed ID: 25604316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing.
    Smolen JS; van der Heijde DM; Aletaha D; Xu S; Han J; Baker D; St Clair EW
    Ann Rheum Dis; 2009 Oct; 68(10):1535-40. PubMed ID: 18957487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tocilizumab: a review of its use in the management of rheumatoid arthritis.
    Oldfield V; Dhillon S; Plosker GL
    Drugs; 2009; 69(5):609-32. PubMed ID: 19368420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tocilizumab in patients with active rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs or tumor necrosis factor inhibitors: subanalysis of Spanish results of an open-label study close to clinical practice.
    Álvaro-Gracia JM; Fernández-Nebro A; García-López A; Guzmán M; Blanco FJ; Navarro FJ; Bustabad S; Armendáriz Y; Román-Ivorra JA;
    Reumatol Clin; 2014; 10(2):94-100. PubMed ID: 24099961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis.
    Dhillon S
    BioDrugs; 2014 Feb; 28(1):75-106. PubMed ID: 24255004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.
    Nishimoto N; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Azuma J
    Ann Rheum Dis; 2009 Oct; 68(10):1580-4. PubMed ID: 19019888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab.
    Klarenbeek NB; Güler-Yüksel M; van der Heijde DM; Hulsmans HM; Kerstens PJ; Molenaar TH; de Sonnaville PB; Huizinga TW; Dijkmans BA; Allaart CF
    Ann Rheum Dis; 2010 Dec; 69(12):2107-13. PubMed ID: 20610442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adalimumab for treating rheumatoid arthritis.
    Navarro-Sarabia F; Ariza-Ariza R; Hernandez-Cruz B; Villanueva I
    Cochrane Database Syst Rev; 2005 Jul; (3):CD005113. PubMed ID: 16034967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.
    Fleischmann RM; Halland AM; Brzosko M; Burgos-Vargas R; Mela C; Vernon E; Kremer JM
    J Rheumatol; 2013 Feb; 40(2):113-26. PubMed ID: 23322466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
    Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
    Ann Rheum Dis; 2017 Jul; 76(7):1279-1284. PubMed ID: 28389552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).
    Kaneko Y; Kato M; Tanaka Y; Inoo M; Kobayashi-Haraoka H; Amano K; Miyata M; Murakawa Y; Yasuoka H; Hirata S; Tanaka E; Miyasaka N; Yamanaka H; Yamamoto K; Takeuchi T;
    Ann Rheum Dis; 2018 Sep; 77(9):1268-1275. PubMed ID: 29853455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of radiographic erosion and joint space narrowing progression in patients with early rheumatoid arthritis: a cohort study.
    Rydell E; Forslind K; Nilsson JÅ; Karlsson M; Åkesson KE; Jacobsson LTH; Turesson C
    Arthritis Res Ther; 2021 Jan; 23(1):27. PubMed ID: 33446222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.
    Aletaha D; Smolen JS
    Arthritis Rheum; 2011 Dec; 63(12):3702-11. PubMed ID: 21953215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study.
    Weinblatt ME; Kremer J; Cush J; Rigby W; Teng LL; Devenport J; Singh N; Lepley D; Genovese MC
    Arthritis Care Res (Hoboken); 2013 Mar; 65(3):362-71. PubMed ID: 22972745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.
    Kubo S; Nakayamada S; Nakano K; Hirata S; Fukuyo S; Miyagawa I; Hanami K; Saito K; Tanaka Y
    Ann Rheum Dis; 2016 Jul; 75(7):1321-7. PubMed ID: 26245754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522).
    Karsdal MA; Schett G; Emery P; Harari O; Byrjalsen I; Kenwright A; Bay-Jensen AC; Platt A
    Semin Arthritis Rheum; 2012 Oct; 42(2):131-9. PubMed ID: 22397953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis.
    Torikai E; Kageyama Y; Takahashi M; Nagano A
    Mod Rheumatol; 2006; 16(6):350-4. PubMed ID: 17164995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.